Goldstein, J. L. & Brown, M. S. A century of cholesterol and coronaries: from plaques to genes to statins. Cell 161, 161–172 (2015).
Luo, J., Yang, H. & Song, B. L. Mechanisms and regulation of cholesterol homeostasis. Nat. Rev. Mol. Cell Biol. 21, 225–245 (2020).
Applebaum-Bowden, D. et al. Down-regulation of the low-density lipoprotein receptor by dietary cholesterol. Am. J. Clin. Nutr. 39, 360–367 (1984).
Feingold, K. R. et al. in Endotext (eds K. R. Feingold et al.) https://www.ncbi.nlm.nih.gov/books/NBK570127/ (National Library of Medicine, 2000).
Horton, J. D., Cuthbert, J. A. & Spady, D. K. Dietary fatty acids regulate hepatic low density lipoprotein (LDL) transport by altering LDL receptor protein and mRNA levels. J. Clin. Invest. 92, 743–749 (1993).
Lecerf, J. M. & de Lorgeril, M. Dietary cholesterol: from physiology to cardiovascular risk. Br. J. Nutr. 106, 6–14 (2011).
Silverman, M. G. et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. J. Am. Med. Assoc. 316, 1289–1297 (2016).
Horton, J. D., Cohen, J. C. & Hobbs, H. H. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 32, 71–77 (2007).
Zelcer, N., Hong, C., Boyadjian, R. & Tontonoz, P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 325, 100–104 (2009).
Newman, C. B. et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler. Thromb. Vasc. Biol. 39, 38–81 (2019).
Ah, Y. M., Jeong, M. & Choi, H. D. Comparative safety and efficacy of low- or moderate-intensity statin plus ezetimibe combination therapy and high-intensity statin monotherapy: a meta-analysis of randomized controlled studies. PLoS ONE 17, e0264437 (2022).
Calapai, F. et al. Adverse reactions to evolocumab: analysis of real-world data from EudraVigilance. Pharmaceuticals 17, 364 (2024).
Tsouka, A. N., Tellis, C. C. & Tselepis, A. D. Pharmacology of PCSK9 inhibitors: current status and future perspectives. Curr. Pharm. Des. 24, 3622–3633 (2018).
van Dam, E. M. & Robinson, P. J. Ral: mediator of membrane trafficking. Int. J. Biochem. Cell Biol. 38, 1841–1847 (2006).
Shirakawa, R. & Horiuchi, H. Ral GTPases: crucial mediators of exocytosis and tumourigenesis. J. Biochem. 157, 285–299 (2015).
Bos, J. L., Rehmann, H. & Wittinghofer, A. GEFs and GAPs: critical elements in the control of small G proteins. Cell 129, 865–877 (2007).
Goldstein, J. L., DeBose-Boyd, R. A. & Brown, M. S. Protein sensors for membrane sterols. Cell 124, 35–46 (2006).
Emmer, B. T. et al. Genome-scale CRISPR screening for modifiers of cellular LDL uptake. PLoS Genet. 17, e1009285 (2021).
Chen, X. W. et al. A Ral GAP complex links PI 3-kinase/Akt signaling to RalA activation in insulin action. Mol. Biol Cell 22, 141–152 (2011).
Wolthuis, R. M., Zwartkruis, F., Moen, T. C. & Bos, J. L. Ras-dependent activation of the small GTPase Ral. Curr. Biol. 8, 471–474 (1998).
Welsch, M. E. et al. Multivalent small-molecule Pan-RAS inhibitors. Cell 168, 878–889.e829 (2017).
Graham, S. E. et al. The power of genetic diversity in genome-wide association studies of lipids. Nature 600, 675–679 (2021).
Broadaway, K. A. et al. Liver eQTL meta-analysis illuminates potential molecular mechanisms of cardiometabolic traits. Am. J. Hum. Genet. 111, 1899–1913 (2024).
Karczewski, K. J. et al. Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes. Cell Genom. 2, 100168 (2022).
Tavori, H., Rashid, S. & Fazio, S. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis 238, 264–270 (2015).
Martin-Gonzalez, A. et al. Selective cargo and membrane recognition by SNX17 regulates its interaction with Retriever. EMBO Rep. 26, 470–493 (2025).
Bartuzi, P. et al. CCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDL. Nat. Commun. 7, 10961 (2016).
Chen, X. W., Leto, D., Chiang, S. H., Wang, Q. & Saltiel, A. R. Activation of RalA is required for insulin-stimulated Glut4 trafficking to the plasma membrane via the exocyst and the motor protein Myo1c. Dev. Cell 13, 391–404 (2007).
Cantor, S. B., Urano, T. & Feig, L. A. Identification and characterization of Ral-binding protein 1, a potential downstream target of Ral GTPases. Mol. Cell. Biol. 15, 4578–4584 (1995).
Timur, Z. K., Akyildiz Demir, S. & Seyrantepe, V. Lysosomal cathepsin A plays a significant role in the processing of endogenous bioactive peptides. Front. Mol. Biosci. 3, 68 (2016).
Galjart, N. J. et al. Human lysosomal protective protein has cathepsin A-like activity distinct from its protective function. J. Biol. Chem. 266, 14754–14762 (1991).
Kolli, N. & Garman, S. C. Proteolytic activation of human cathepsin A. J. Biol. Chem. 289, 11592–11600 (2014).
Seyrantepe, V. et al. Enzymatic activity of lysosomal carboxypeptidase (cathepsin) A is required for proper elastic fiber formation and inactivation of endothelin-1. Circulation 117, 1973–1981 (2008).
Yan, C. et al. Discovery and characterization of small molecules that target the GTPase Ral. Nature 515, 443–447 (2014).
Cowling, R. T. Cathepsin A inhibitors to treat heart disease: much potential, many questions. JACC Basic Transl. Sci. 4, 345–347 (2019).
Tillner, J. et al. Tolerability, safety, and pharmacokinetics of the novel cathepsin A inhibitor SAR164653 in healthy subjects. Clin. Pharmacol. Drug Dev. 5, 57–68 (2016).
Chen, X. W. & Saltiel, A. R. Ral’s engagement with the exocyst: breaking up is hard to do. Cell Cycle 10, 2299–2304 (2011).
Zhou, Y. & Hancock, J. F. Lipid profiles of RAS Nanoclusters regulate RAS function. Biomolecules 11, 1439 (2021).
Zhu, Y. et al. Lipoprotein promotes caveolin-1 and Ras translocation to caveolae: role of cholesterol in endothelial signaling. Arterioscler. Thromb. Vasc. Biol. 20, 2465–2470 (2000).
Richardson, D. S., Spehar, J. M., Han, D. T., Chakravarthy, P. A. & Sizemore, S. T. The RAL enigma: distinct roles of RALA and RALB in cancer. Cells 11, 1645 (2022).
Neyraud, V. et al. RalA and RalB proteins are ubiquitinated GTPases, and ubiquitinated RalA increases lipid raft exposure at the plasma membrane. J. Biol. Chem. 287, 29397–29405 (2012).
Martin, T. D., Mitin, N., Cox, A. D., Yeh, J. J. & Der, C. J. Phosphorylation by protein kinase Calpha regulates RalB small GTPase protein activation, subcellular localization, and effector utilization. J. Biol. Chem. 287, 14827–14836 (2012).
Goldstein, J. L. & Brown, M. S. The LDL receptor. Arterioscler. Thromb. Vasc. Biol. 29, 431–438 (2009).
Takeda, T. et al. Upregulation of IGF2R evades lysosomal dysfunction-induced apoptosis of cervical cancer cells via transport of cathepsins. Cell Death Dis. 10, 876 (2019).
Itoh, K. & Tsukimoto, J. Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent. Glycoconj. J. 40, 611–619 (2023).
Skorobogatko, Y. et al. RalA controls glucose homeostasis by regulating glucose uptake in brown fat. Proc. Natl Acad. Sci. USA 115, 7819–7824 (2018).
Leto, D. & Saltiel, A. R. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat. Rev. Mol. Cell Biol. 13, 383–396 (2012).
Xia, W. et al. Obesity causes mitochondrial fragmentation and dysfunction in white adipocytes due to RalA activation. Nat. Metab 6, 273–289 (2024).
Platt, R. J. et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159, 440–455 (2014).
Feng, X. et al. Dual function of VGLL4 in muscle regeneration. EMBO J. 38, e101051 (2019).
Abu-Remaileh, M. et al. Lysosomal metabolomics reveals V-ATPase- and mTOR-dependent regulation of amino acid efflux from lysosomes. Science 358, 807–813 (2017).
Zhang, B. et al. Hepatic glycogen directly regulates gluconeogenesis through an AMPK/CRTC2 axis in mice. J. Clin. Invest. 135, e188363 (2025).
Liu, X. et al. Isolation of primary human liver cells from normal and nonalcoholic steatohepatitis livers. STAR Protoc. 4, 102391 (2023).
Feng, X. et al. The tumor suppressor interferon regulatory factor 2 binding protein 2 regulates hippo pathway in liver cancer by a feedback loop in mice. Hepatology 71, 1988–2004 (2020).
de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput. Biol. 11, e1004219 (2015).
Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 10, e1004383 (2014).
Feng, X. Mouse liver proteomic data From RalA-WT, RalA-G23V or RalA-S28N overexpression. Figshare https://doi.org/10.6084/m9.figshare.32229999 (2026).
